临床试验/NCT03906344

NCT03906344No Longer Available不适用

Expanded Access Use of INCB052793 to Treat a Single Patient With Myelofibrosis

Incyte Corporation0 个研究点开始时间: 2019年4月8日最近更新: 2019年4月8日

相关药物

试验速览

阶段: 不适用
状态: No Longer Available
发起方: Incyte Corporation

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

Expanded access use of INCB052793 to treat a single patient with Myelofibrosis.

研究设计

研究类型: Expanded Access

入排标准

接受健康志愿者: 否

入选标准

未提供

排除标准

未提供

研究者

发起方

Incyte Corporation

申办方类型

Industry

责任方

Sponsor

相似试验

No Longer Available

Expanded Access Use of INCB054329 to Treat a Single Patient With Metastatic Renal Cell Carcinoma

NCT03896815Incyte Corporation

Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 MutationAdvanced Non-small Cell Lung CancerCancer

NCT06761976Bayer

Expanded Access to ZiftomenibAcute Lymphoblastic Leukemia, With Appropriate MutationsAcute Myeloid Leukemia, With NPM1 MutationsAcute Lymphoblastic Leukemia, With KMT2A RearrangementsAcute Myeloid Leukemia, With KMT2A Rearrangements

NCT05738538Kura Oncology, Inc.

Expanded Access Use of Itacitinib to Treat a Single Patient With STAT1 Gain of Function (GOF) DiseaseSTAT1 Gain-of-Function Disease

NCT05561985Incyte Corporation

Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Treatment of SCISpinal Cord Injury at C5-C7 Level

NCT03925649Hope Biosciences LLC